Modulating Nitrosourea Response In Tumors And Normal Tissue: Application To Fotemustine
geoffrey p margison,j a rafferty,rhoderick h elder,john m kelly,a j watson,mark andrew willington,s m lee,ian d hickson,l j fairbaim,t m dexter,j jelinek,carol stocking,christopher baum,wolfram ostertag,s eghyazi,johan hansson,ulrik ringborg,dorothy j donnelly,tbh mcmurry,joan e mccormick,r s mcelhinney
1996-01-01
Drugs of Today
Abstract:Fotemustine (Muphoran(R)) is a chloroethylnitrosourea (CNU) and, by analogy with other CNUs, its principal mechanism of cell killing is likely to be via the formation of a chloroethylating species that generates C-G interstrand cross-links in DNA following an initial chloroethylation reaction at the O-6-position of guanine residues. CNU-mediated DNA cross-link formation can be prevented by the action of the DNA repair protein, O-6-alkylguanine-DNA alkyltransferase (ATase), on the initial O-6-chloroethylguanine monoadduct. Several groups have shown that overexpression of ATase in mammalian cells in culture following transfection of pro- or eukaryotic ATase-encoding expression vectors protects against the toxic effects of CNUs, including fotemustine, demonstrating that this is indeed the principal mechanism of resistance to such agents, although other mechanisms, including the action of DNA glycosylases, cannot be discounted. Many of the tumor types that we have immunostained with anti-human ATase antibodies express high levels of this protein, but regional variations in immunostaining within a tumor and different levels of immunostaining in different melanoma metastases from the same patient have also been seen. On the other hand, bone marrow, the principal site of dose-limiting toxicity for most nitrosoureas, generally expresses relatively little ATase activity. ATase in tumor cells can be depleted by the administration of O-6-alkylguanines that act as substrates for the protein, and this increases the growth inhibitory effect of CNUs and related agents in several human tumor xenografts grown in nude mice. Increasing the ATase levels in murine bone marrow by the ex vivo transduction of retroviruses encoding human ATase into bone marrow cells decreases their sensitivity to the toxic effects of this class of agents. Similar modulation of ATase levels might, therefore, be expected to increase the therapeutic index of fotemustine and other CNUs when used clinically.